[Abstract Only] Randomized Trial: SGLT2 Inhibitor Improves Outcomes in Patients with Heart Failure Even in the Absence of Diabetes

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction – New England Journal of Medicine (link to abstract – $ for full-text)

Related 2019 ESC Congress News Release, Before Publication: Randomized Trial: SGLT2 inhibitors Seems Beneficial for Heart Failure Even in Nondiabetics (free commentaries)

Commentaries: SGLT2 Inhibitor Dapagliflozin Lowers Risk for Worsening Heart Failure – NEJM Journal Watch (free) AND New research shows dapagliflozin used to treat diabetes can also treat heart failure, in patients with and without diabetes (the DAPA-HF Study) – Diabetologia (free)